CRISPR Therapeutics AGCRSPNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-64.55%
↓ 683% below average
Average (39q)
11.08%
Historical baseline
Range
High:129.22%
Low:-64.55%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -64.55% |
| Q2 2025 | 129.22% |
| Q1 2025 | -11.77% |
| Q4 2024 | -0.01% |
| Q3 2024 | 9.08% |
| Q2 2024 | 5.58% |
| Q1 2024 | -25.02% |
| Q4 2023 | 4.90% |
| Q3 2023 | -10.69% |
| Q2 2023 | 1.62% |
| Q1 2023 | -3.50% |
| Q4 2022 | -11.20% |
| Q3 2022 | -5.36% |
| Q2 2022 | 4.21% |
| Q1 2022 | 14.70% |
| Q4 2021 | 23.47% |
| Q3 2021 | 1.42% |
| Q2 2021 | 16.58% |
| Q1 2021 | -14.26% |
| Q4 2020 | 15.99% |
| Q3 2020 | 19.58% |
| Q2 2020 | 9.57% |
| Q1 2020 | 11.14% |
| Q4 2019 | -14.82% |
| Q3 2019 | 44.81% |
| Q2 2019 | 16.89% |
| Q1 2019 | 17.43% |
| Q4 2018 | -27.67% |
| Q3 2018 | 55.35% |
| Q2 2018 | 31.32% |
| Q1 2018 | -2.55% |
| Q4 2017 | 12.24% |
| Q3 2017 | 4.23% |
| Q2 2017 | 15.64% |
| Q1 2017 | -4.93% |
| Q4 2016 | 29.21% |
| Q3 2016 | 40.11% |
| Q2 2016 | 43.08% |
| Q1 2016 | -2.62% |
| Q4 2015 | 64.68% |